medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2023, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2023; 21 (4)

Onychomycosis in pediatric patients: a retrospective study in the Mexican population

Medina VNA, López MJC, Vega SDC, Arenas R

Language: Spanish
References: 18
Page: 287-291
PDF size: 218.71 Kb.


Text Extraction

Background: onychomycosis is uncommon in the pediatric population, however in recent years an increase in worldwide prevalence has been observed. Diagnosis should be confirmed by mycological examination and family members of affected individuals should be examined to rule out onychomycosis and tinea pedis.
Objective: to determine the epidemiological and mycological aspects of onychomycosis in pediatric patients in the Mycology Section at Dr. Manuel Gea González General Hospital.
Methodology: retrospective, observational, descriptive and cross-sectional study. Compiling data from the Mycology Section at Manuel Gea González General Hospital, since January 2008 to December 2022, of newborn patients to 16 years of age with suspected onychomycosis.
Results: the average age at diagnosis was 9.8 years. It occurred more frequently in men (56.17%). In 96.6% the toenails were affected and the most common clinical variety was distal and lateral subungual onychomycosis (50.5%). The most common etiologic agent was Trichophyton rubrum. The most related disease was asthma in 4.4%. They were associated with other superficial mycoses in eight cases (10.1%), six patients with tinea pedis (6.7%) and two with tinea corporis (2.2%).
Conclusions: Onychomycosis in the pediatric population was found more frequently in adolescents and the most common etiologic agent was T. rubrum. Emphasis is made in increase of the prevalence of onychomycosis in recent years and the importance of mycological examination.


REFERENCES

  1. Ramírez Cortés E, Saucedo Montes EE, Arenas Guzmán R ySolórzano Santos F, Onicomicosis en pacientes pediátricos, EnfermedadesInfecciosas y Microbiología 2020;39(1):28-35.

  2. Solís-Arias MP y García-Romero MT, Onychomycosis in children.A review, Int J Dermatol 2017; 56(2):123-30.

  3. Alfaro DA y González CG, Onicomicosis en pediatría: actualizacióny tratamiento, Rev Chil Pediatr 2020; 91(1):131-8.

  4. Eichenfield LF y Friedlander SF, Pediatric onychomycosis:the emerging role of topical therapy, J Drugs Dermatol 2017;1,16(2):105-9.

  5. Mercado EV y Arenas R, Onicomicosis en niños. Estudio retrospectivode 233 casos mexicanos, Gac Med Mex 2008; 144(1):7-10.

  6. Song G, Zhang M, Liu W y Liang G, Children onychomycosis, aneglected dermatophytosis: a retrospective study of epidemiologyand treatment, Mycoses 2023; 66(5):448-54.

  7. Starace M, Alessandrini A y Piraccini BM, Nail disorders in children,Skin Append Disord 2018; 4(4):217-29.

  8. Alfaro DA y González CG, Onicomicosis en pediatría: actualizacióny tratamiento, Rev Chil Pediatr 2020; 91(1):131-8.

  9. Asz-Sigall D, Tosti A y Arenas R, Tinea unguium: diagnosis andtreatment in practice, Mycopathologia 2016; 182(1-2): 95-100.

  10. Gupta AK, Versteeg SG y Shear NH, Onychomycosis in the 21stcentury: an update on diagnosis, epidemiology, and treatment,J Cutan Med Surg 2017; 21(6):525-39.

  11. García-Romero MT, Granados J, Vega-Memije ME y Arenas R,Análisis del polimorfismo genético de los loci hla-b y hla-dr enpacientes con onicomicosis dermatofítica y familiares en primergrado, Actas Dermosifiliogr 2012; 103(1):59-62.

  12. Vestergaard-Jensen S, Mansouri A, Jensen LH, Jemec GBE ySaunte DML, Systematic review of the prevalence of onychomycosisin children, Pediatr Dermatol 2022; 6:855-65.

  13. Falotico JM y Lipner SR, Updated perspectives on the diagnosisand management of onychomycosis, Clin Cosmet Investig Dermatol2022; 15,15:1933-57.

  14. Gupta AK, Mays RR, Versteeg SG, Shear NH y Friedlander SF,Onychomycosis in children: safety and efficacy of antifungalagents, Pediatr Dermatol 2018; 35(5):552-9.

  15. Ameen M, Lear JT, Madan V, Mohd Mustapa MF y RichardsonM, British Association of Dermatologists’ guidelines for themanagement of onychomycosis 2014; 171(5):937-58.

  16. Lipner SR, Joseph WS, Vlahovic TC, Scher RK, Rich P, GhannoumM et al., Therapeutic recommendations for the treatmentof toenail onychomycosis in the US, J Drugs Dermatol 2021;20(10):1076-84.

  17. Gupta AK y Talukder M, Efinaconazole in onychomycosis, Am JClin Dermatol 2022; 23(2):207-18.

  18. Foley K, Gupta AK, Versteeg S, Mays R, Villanueva E y John D,Topical and device-based treatments for fungal infections of thetoenails, Cochrane Database Syst Rev 2020; 16,1(1):cd012093.




2020     |     www.medigraphic.com